# EDGAR Filing Document

**Accession Number:** 0001734768
**File Stem:** 0001176256-23-000045
**Filing Date:** 2023-3
**Character Count:** 7671
**Document Hash:** 85923711724bcf956b3f469ad298c938
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001176256-23-000045.hdr.sgml**: 20230309

**ACCESSION NUMBER**: 0001176256-23-000045

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 3

**CONFORMED PERIOD OF REPORT**: 20230309

**FILED AS OF DATE**: 20230309

**DATE AS OF CHANGE**: 20230309

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** IMV Inc.
- **CENTRAL INDEX KEY:** 0001734768
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 000000000
- **STATE OF INCORPORATION:** Z4
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-38480
- **FILM NUMBER:** 23718851

**BUSINESS ADDRESS:**
- **STREET 1:** 130 EILEEN STUBBS AVE.
- **STREET 2:** SUITE 19
- **CITY:** DARTMOUTH
- **STATE:** A5
- **ZIP:** B3B 2C4
- **BUSINESS PHONE:** 9024921819

**MAIL ADDRESS:**
- **STREET 1:** 130 EILEEN STUBBS AVE.
- **STREET 2:** SUITE 19
- **CITY:** DARTMOUTH
- **STATE:** A5
- **ZIP:** B3B 2C4

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Immunovaccine Inc.
- **DATE OF NAME CHANGE:** 20180316

------

**UNITED STATES<br>SECURITIES AND EXCHANGE COMMISSION**<br>**Washington, D.C. 20549**

**FORM 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 <br>UNDER THE SECURITIES EXCHANGE ACT OF 1934**

For the month of **March, 2023**

Commission File Number: **001-38480**

**<u>IMV Inc.</u>**<br> (*Name of registrant*)

**130 Eileen Stubbs Avenue, Suite 19 <br>Dartmouth, Nova Scotia <br><u>B3B 2C4, Canada</u>**

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

[ ] Form 20-F [ X ] Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): [ ]

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): [ ]<br>

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **IMV Inc.** | **IMV Inc.** |
| Date: March 9, 2023 | By: | <u>/s/ Brittany Davison</u> |
|  |  | Name: Brittany Davison |
|  |  | Title: Chief Accounting Officer |

---

------

**Form 6-K Exhibit Index**

---

| | |
|:---|:---|
| **Exhibit**<br>**Number** | **Document Description** |
| [99.1](exhibit99-1.htm) | [IMV Inc. to Announce Fourth Quarter and Fiscal Year 2022 Results and Host a Conference Call and Webcast on March 16, 2023](exhibit99-1.htm) |

---

------

## Exhibit 99.1

------

**Exhibit 99.1**

Media Release ![](exhibit99-1x1x1.jpg) <br>

**IMV Inc. to Announce Fourth Quarter and Fiscal Year 2022 Results and Host a Conference Call and Webcast on March 16, 2023**

**Dartmouth, Nova Scotia, and Cambridge, Mass., March 9, 2023** , IMV Inc. (NASDAQ: IMV; TSX: IMV), a clinical-stage company developing a portfolio of immune-educating therapies, based on its novel DPX platform, to treat solid and hematologic cancers, today announced that it will hold a conference call and webcast on Thursday, March 16, 2023, at 8:00 a.m. ET to discuss the company's 2022 fourth quarter and fiscal year-end financial and operational results.

Financial analysts are invited to join the conference call by registering at this <u>link</u> prior the call to receive their individual dial-in information.

Other interested parties will be able to access the live audio webcast at this link: <u>https://ir.imv-inc.com/events-and-presentations</u>. The webcast will be recorded and will then be available on the IMV website for 30 days following the call.

**About IMV**

IMV Inc. is a clinical-stage immuno-oncology company advancing a portfolio of therapies based on the Company's immune-educating platform, DPX<sup>®</sup>. Through a differentiated mechanism of action, the DPX platform delivers instruction to the immune system to generate a specific, robust, and persistent immune response. IMV's lead candidate, maveropepimut-S (MVP-S), delivers antigenic peptides from survivin, a well-recognized cancer antigen commonly overexpressed in advanced cancers. MVP-S also delivers an innate immune activator and a universal CD4 T cell helper peptide. These elements foster maturation of antigen presenting cells as well as robust activation of CD8 T cell effector and memory function. MVP-S treatment has been well tolerated and has demonstrated defined clinical benefit in multiple cancer indications as well as the activation of a targeted and sustained, survivin-specific anti-tumor immune response. MVP-S is currently being evaluated in clinical trials for hematologic and solid cancers, including Diffuse Large B Cell Lymphoma (DLBCL) as well as ovarian, bladder and breast cancers. IMV is also developing a second immunotherapy leveraging the DPX immune delivery platform, DPX-SurMAGE. This dual-targeted immunotherapy combines antigenic peptides for both the survivin and MAGE-A9 cancer proteins to elicit immune responses to these two distinct cancer antigens simultaneously. A Phase 1 clinical trial in bladder cancer, using MVP-S or DPX-SurMAGE, was initiated in early 2022. For more information, visit <u>www.imv-inc.com</u> and connect with us on <u>Twitter</u> and <u>LinkedIn</u>.<br>

------

**IMV Forward-Looking Statements**

This press release contains forward-looking information under applicable securities law. All information that addresses activities or developments that we expect to occur in the future is forward-looking information. Forward-looking statements use such word as "will", "may", "potential", "believe", "expect", "continue", "anticipate" and other similar terminology. Forward-looking statements are based on the estimates and opinions of management on the date the statements are made. In this press release,such forward-looking statements include, but are not limited to, statements regarding the potential and efficacy of MVP-S, the potential impact of the VITALIZE study and timing of availability of the ORR from the remaining stage one patients from its Phase 2B trial, the Company's ability to advance its development strategy, and the prospects for its lead immunotherapy and its other pipeline of immunotherapy candidates. IMV Inc. assumes no responsibility to update forward-looking statements in this press release except as required by law. These forward-looking statements involve known and unknown risks and uncertainties, and those risks and uncertainties include, but are not limited to, those related to the detailed results when presented being at least consistent with the initial results from the VITALIZE Phase 2B trial, the Company's priorities with MVP-S and its DPX delivery platform, the potential for its delivery platform and the anticipated timing of enrollment and results for its clinical trial programs and studies as other risks detailed from time to time in our ongoing quarterly filings and annual information form. Investors are cautioned not to rely on these forward-looking statements and are encouraged to read IMV's continuous disclosure documents, including its current annual information form, as well as its audited annual consolidated financial statements which are available on SEDAR at <u>www.sedar.com</u> and on EDGAR at <u>www.sec.gov/edgar</u>.

**Investor Relations & Media**

**Delphine Davan<br>Senior Director, Communications and Investor Relations <br>IMV Inc.**

O: (902) 492.1819 ext: 1049 <br>E: <u>ddavan@imv-inc.com</u>

Source: IMV Inc.<br>

------